BMY - Bristol Myers posts long-term data for heart-disease drug in late-stage trial

Bristol Myers Squibb (NYSE:BMY) shared new interim data from a late-stage study to indicate that its oral cardiac myosin inhibitor, mavacamten led to sustained improvements in clinically meaningful cardiovascular outcomes in patients with symptomatic obstructive hypertrophic cardiomyopathy. The EXPLORER-LTE cohort involved 231 of the 244 patients who were eligible to undergo the long-term extension study at the end of Phase 3 EXPLORER-HCM study. More than 200 patients remained in the study for over 48 weeks, while 67 had reached 84 weeks. The key findings include a sustained decrease in left ventricular outflow tract (LVOT) gradients with a decline of -35.6 mmHg ± 32.6 mmHg at Week 48 from the baseline. According to the company, similar reductions were seen throughout the extension period (up to 84 weeks). Meanwhile, the safety profile of the drug was found to be in line with the EXPLORER-HCM trial, the results of which were announced in May. Mavacamten

For further details see:

Bristol Myers posts long-term data for heart-disease drug in late-stage trial